(VTVT)
0.00
0.00 (0.00%)
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
0.00
0.00 (0.00%)
vTv Therapeutics Inc. kechki bosqichdagi biofarmatsevtika kompaniyasi bo'lib, diabet va boshqa surunkali kasalliklar bilan yashovchi odamlarni davolash uchun mo'ljallangan og'iz orqali yuboriladigan kichik molekulali dori nomzodlarini ishlab chiqishga qaratilgan. Uning yetakchi dori nomzodi kadisegliatin (TTP399) bo'lib, og'iz orqali yuboriladigan kichik molekula va jigar-selektiv glyukokinaza aktivatori bo'lib, 1-toifa diabetni davolash uchun III bosqich klinik sinovlarida. Kompaniya shuningdek, surunkali kasalliklar uchun turli ko'rsatmalarga ega bir qator molekulalarga sarmoya kiritmoqda. Uda fosfodiesteraza tip 4 ingibitorlari dasturini ishlab chiqish va tijoratlashtirish uchun Newsoara Biopharma Co., Ltd. bilan litsenzion kelishuvi mavjud. vTv Therapeutics Inc. 2015 yilda tashkil etilgan va shtab-kvartirasi Shimoliy Karolina shtatining High Point shahrida joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Carmen Valcarce Ph.D. | Chief Scientific Officer & Executive VP |
| Dr. Michael Steven Tung M.B.A., M.D. | Executive VP & CFO |
| Dr. Thomas Strack M.D., Ph.D. | Chief Medical Officer |
| Mr. Barry K. Brown | Chief Accounting Officer |
| Mr. Martin Lafontaine | Chief Commercial Officer |
| Mr. Paul J. Sekhri | CEO, President & Chairman of the Board |
| Mr. Richard S. Nelson | Executive VP of Corporate Development & Director |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-03-10 | 8-K | vtvt-20260310.htm |
| 2026-02-02 | 8-K | vtvt-20260130.htm |
| 2025-12-19 | 8-K | vtvt-20251219.htm |
| 2025-11-06 | 8-K | vtvt-20251106.htm |
| 2025-10-03 | S-3 | d92646ds3.htm |
| 2025-09-10 | 8-K | vtvt-20250910.htm |
| 2025-09-02 | 8-K | d52598d8k.htm |
| 2025-08-12 | 8-K | vtvt-20250812.htm |
| 2025-06-12 | 8-K | vtvt-20250610.htm |
| 2025-05-19 | 8-K | vtvt-20250519.htm |
| Ms. Elizabeth M. Keiley |
| Executive VP & General Counsel |